In the study by Golan et al. [71] of patients with pancreatic cancer with BRCA mutations, a slightly more favourable median all-stage OS was reported for patients with PDAC and BRCA1/2 mutations. This evidence concerns the gene BRCA1 and pancreatic neoplasm.